Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Stomach Neoplasms 1Recurrence 1Peripheral Nervous System Diseases 1Hodgkin Disease 1Disseminated Intravascular Coagulation 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Age Problem 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Fumigant 93 × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
35 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡